Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.

@article{Gurin2002DosedependentAO,
  title={Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.},
  author={Maryse Gu{\'e}rin and Pascal Egger and C{\'e}line Soudant and W Le Goff and Arie van Tol and Reynald Dupuis and M. John Chapman},
  journal={Atherosclerosis},
  year={2002},
  volume={163 2},
  pages={
          287-96
        }
}
Type IIB hyperlipidemia is associated with premature vascular disease, an atherogenic lipoprotein phenotype characterised by elevated levels of triglyceride-rich VLDL and small dense LDL, together with subnormal levels of HDL. The dose-dependent and independent effects of a potent HMGCoA reductase inhibitor, Atorvastatin, at daily doses of 10 and 40 mg, were evaluated on triglyceride-rich lipoprotein subclasses (VLDL-1, VLDL-2 and IDL), on the major LDL subclasses (light LDL, LDL-1+LDL-2, D: 1… CONTINUE READING
Highly Cited
This paper has 45 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 22 citations